$ATOS
ATOSSA THERAPEUTICS, INC.

2013 Q4 Form 10-Q Financial Statement

#000114420413060511 Filed on November 12, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $50.00K $76.60K $100.0K
YoY Change -50.0% -27.45%
Cost Of Revenue $30.00K $25.94K $10.00K
YoY Change 200.0% 188.2% 0.0%
Gross Profit $20.00K $50.66K $90.00K
YoY Change -77.78% -44.02%
Gross Profit Margin 40.0% 66.14% 90.0%
Selling, General & Admin $2.250M $3.231M $1.330M
YoY Change 69.17% 376.57% 23.15%
% of Gross Profit 11250.0% 6378.82% 1477.78%
Research & Development $370.0K $321.1K $470.0K
YoY Change -21.28% -41.41%
% of Gross Profit 1850.0% 633.87% 522.22%
Depreciation & Amortization $120.0K $27.17K $100.0K
YoY Change 20.0% 171.65% 900.0%
% of Gross Profit 600.0% 53.62% 111.11%
Operating Expenses $2.630M $3.553M $1.790M
YoY Change 46.93% 189.73% 67.29%
Operating Profit -$2.610M -$3.502M -$1.700M
YoY Change 53.53% 208.35% 58.88%
Interest Expense $0.00 $1.00 $0.00
YoY Change -99.99% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.760M -$3.502M -$1.710M
YoY Change 61.4% 206.27% 44.92%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.760M -$3.502M -$1.710M
YoY Change 61.4% 206.27% 44.92%
Net Earnings / Revenue -5520.0% -4571.78% -1710.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$27.60M -$38.89M -$19.00M
COMMON SHARES
Basic Shares Outstanding 18.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.300M $7.700M $1.700M
YoY Change 270.59% 1825.0% -10.53%
Cash & Equivalents $6.342M $7.694M $1.725M
Short-Term Investments
Other Short-Term Assets $300.0K $600.0K $100.0K
YoY Change 200.0% 100.0% -90.0%
Inventory $0.00 $0.00
Prepaid Expenses $932.6K $559.4K $122.6K
Receivables $139.1K $299.3K $141.7K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.762M $8.595M $1.989M
YoY Change 239.88% 855.05% -31.4%
LONG-TERM ASSETS
Property, Plant & Equipment $163.1K $443.3K $160.0K
YoY Change 1.99% 343.27% 59.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $36.45K $4.444M $4.677M
YoY Change -99.22%
Total Long-Term Assets $5.247M $4.887M $4.837M
YoY Change 8.49% 1.81% 2318.32%
TOTAL ASSETS
Total Short-Term Assets $6.762M $8.595M $1.989M
Total Long-Term Assets $5.247M $4.887M $4.837M
Total Assets $12.01M $13.48M $6.826M
YoY Change 75.93% 136.53% 120.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $248.1K $31.13K $68.22K
YoY Change 263.75% -68.87% -31.78%
Accrued Expenses $295.3K $1.400M $1.582M
YoY Change -81.34% -26.32% 295.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.402M $1.942M $1.651M
YoY Change -15.09% -15.55% 10.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.402M $1.942M $1.651M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.407M $1.900M $1.700M
YoY Change -17.21% -17.39% 13.33%
SHAREHOLDERS EQUITY
Retained Earnings -$20.52M -$17.76M -$9.732M
YoY Change 110.82%
Common Stock $18.57K $17.45K $12.92K
YoY Change 43.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.60M $11.54M $5.176M
YoY Change
Total Liabilities & Shareholders Equity $12.01M $13.48M $6.826M
YoY Change 75.93% 136.53% 120.2%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income -$2.760M -$3.502M -$1.710M
YoY Change 61.4% 206.27% 44.92%
Depreciation, Depletion And Amortization $120.0K $27.17K $100.0K
YoY Change 20.0% 171.65% 900.0%
Cash From Operating Activities -$2.650M -$2.740M -$1.930M
YoY Change 37.31% 1726.67% 85.58%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K -$310.0K -$130.0K
YoY Change -30.77% 160.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K -$310.0K -$130.0K
YoY Change -30.77% 160.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.390M 8.300M 3.370M
YoY Change -58.75% 1593.88%
NET CHANGE
Cash From Operating Activities -2.650M -2.740M -1.930M
Cash From Investing Activities -90.00K -310.0K -130.0K
Cash From Financing Activities 1.390M 8.300M 3.370M
Net Change In Cash -1.350M 5.250M 1.310M
YoY Change -203.05% 1444.12% -220.18%
FREE CASH FLOW
Cash From Operating Activities -$2.650M -$2.740M -$1.930M
Capital Expenditures -$90.00K -$310.0K -$130.0K
Free Cash Flow -$2.560M -$2.430M -$1.800M
YoY Change 42.22% 1520.0% 81.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7693561 USD
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
122633 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
1989495 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1725197 USD
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Amendment Flag
AmendmentFlag
false
CY2013Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
559386 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
8595445 USD
dei Document Type
DocumentType
10-Q
us-gaap Sales Revenue Net
SalesRevenueNet
585345 USD
dei Trading Symbol
TradingSymbol
ATOS
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
141665 USD
CY2013Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
43160 USD
CY2012Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
0 USD
CY2013Q3 atos Furniture And Equipment Net
FurnitureAndEquipmentNet
443272 USD
CY2012Q4 atos Furniture And Equipment Net
FurnitureAndEquipmentNet
159967 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
443272 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
159967 USD
CY2013Q3 us-gaap Security Deposit
SecurityDeposit
36446 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4407058 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4640224 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4443504 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4676671 USD
CY2013Q3 us-gaap Assets
Assets
13482221 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
31131 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
68217 USD
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18024824 shares
dei Entity Registrant Name
EntityRegistrantName
ATOSSA GENETICS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001488039
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012Q4 us-gaap Assets
Assets
6826133 USD
us-gaap Sales Revenue Net
SalesRevenueNet
383386 USD
us-gaap Sales Revenue Net
SalesRevenueNet
1068687 USD
CY2009Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
299338 USD
CY2012Q4 us-gaap Security Deposit
SecurityDeposit
36447 USD
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20300 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1942272 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4288644 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
590359 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6600819 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
90499 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
50659 USD
us-gaap Gross Profit
GrossProfit
270783 USD
CY2013Q3 atos Accrued Expenses Current
AccruedExpensesCurrent
1069759 USD
CY2012Q4 atos Accrued Expenses Current
AccruedExpensesCurrent
1374385 USD
CY2013Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
60753 USD
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0 USD
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
357489 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
207996 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1650598 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 atos Diagnostic Testing Service
DiagnosticTestingService
72187 USD
CY2012Q3 atos Diagnostic Testing Service
DiagnosticTestingService
104011 USD
atos Diagnostic Testing Service
DiagnosticTestingService
361905 USD
atos Diagnostic Testing Service
DiagnosticTestingService
376696 USD
atos Diagnostic Testing Service
DiagnosticTestingService
837307 USD
CY2013Q3 atos Product Sales
ProductSales
4410 USD
CY2012Q3 atos Product Sales
ProductSales
1565 USD
atos Product Sales
ProductSales
223440 USD
atos Product Sales
ProductSales
6690 USD
atos Product Sales
ProductSales
231380 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
17445 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
12919 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
76597 USD
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
105576 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29281396 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14894522 USD
CY2013Q3 us-gaap Cost Of Services
CostOfServices
25938 USD
CY2012Q3 us-gaap Cost Of Services
CostOfServices
9000 USD
us-gaap Cost Of Services
CostOfServices
75893 USD
us-gaap Cost Of Services
CostOfServices
29985 USD
us-gaap Cost Of Services
CostOfServices
111638 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17758892 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9731906 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
238669 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
243833 USD
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
25938 USD
CY2012Q3 us-gaap Cost Of Revenue
CostOfRevenue
9000 USD
us-gaap Cost Of Revenue
CostOfRevenue
314562 USD
us-gaap Cost Of Revenue
CostOfRevenue
29985 USD
us-gaap Cost Of Revenue
CostOfRevenue
355471 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
11539949 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
5175535 USD
CY2013Q3 atos Loss On Reduction Of Inventory To Lower Of Cost Or Market
LossOnReductionOfInventoryToLowerOfCostOrMarket
0 USD
CY2012Q3 atos Loss On Reduction Of Inventory To Lower Of Cost Or Market
LossOnReductionOfInventoryToLowerOfCostOrMarket
6077 USD
atos Loss On Reduction Of Inventory To Lower Of Cost Or Market
LossOnReductionOfInventoryToLowerOfCostOrMarket
0 USD
atos Loss On Reduction Of Inventory To Lower Of Cost Or Market
LossOnReductionOfInventoryToLowerOfCostOrMarket
29884 USD
atos Loss On Reduction Of Inventory To Lower Of Cost Or Market
LossOnReductionOfInventoryToLowerOfCostOrMarket
121910 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13482221 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6826133 USD
us-gaap Gross Profit
GrossProfit
323517 USD
us-gaap Gross Profit
GrossProfit
591306 USD
CY2013Q3 us-gaap Selling Expense
SellingExpense
373418 USD
CY2012Q3 us-gaap Selling Expense
SellingExpense
87704 USD
us-gaap Selling Expense
SellingExpense
965383 USD
us-gaap Selling Expense
SellingExpense
281971 USD
us-gaap Selling Expense
SellingExpense
1605259 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
321111 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
548108 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
731258 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1508944 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2858027 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1896254 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12423155 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
3552556 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
1226171 USD
us-gaap Operating Expenses
OperatingExpenses
8297460 USD
us-gaap Operating Expenses
OperatingExpenses
3687169 USD
us-gaap Operating Expenses
OperatingExpenses
18317058 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3501897 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1135672 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8026677 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3363652 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-17725752 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
53 USD
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
46 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
53 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1219 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
6641 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
1 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
7756 USD
us-gaap Interest Expense
InterestExpense
360 USD
us-gaap Interest Expense
InterestExpense
11816 USD
us-gaap Interest Expense
InterestExpense
39531 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3501845 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1143382 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8026984 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3374249 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17758642 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
250 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3501845 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-1143382 USD
us-gaap Net Income Loss
NetIncomeLoss
-8026984 USD
us-gaap Net Income Loss
NetIncomeLoss
-3374249 USD
us-gaap Net Income Loss
NetIncomeLoss
-17758892 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15830033 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11256867 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14697221 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11256867 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9127656 shares
CY2013Q3 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
402840 USD
CY2012Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
0 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
402928 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
115095 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17444824 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17444824 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12919367 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12919367 shares
us-gaap Nature Of Operations
NatureOfOperations
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">NOTE 1: NATURE OF OPERATIONS</font></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearances for marketing, which acquisition was completed in January 2009. Atossa Genetics Inc. (the &#8220;Company&#8221;) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the MASCT System, which was cleared by the FDA in 2003 as a medical device that is intended for use in the collection of nipple aspirate fluid for laboratory cytological testing.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The Company&#8217;s fiscal year ends on December 31st.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In December 2011, the Company established the National Reference Laboratory for Breast Health, or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company&#8217;s CLIA-certified laboratory where the ForeCYTE and ArgusCYTE test specimens are examined by cytopathology.&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (&#8220;Acueity&#8221;). The purchased assets included 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries) and 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizations related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font>. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On October 4, 2013 the Company commenced the voluntary recall of the ForeCYTE Breast Health Test (also known as the MASCT System or ForeCYTE Test).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> As a result of this recall, this product is currently not being marketed or distributed in the U.S.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font> The Company intends to obtain an additional FDA 510(k) clearance from the FDA for the ForeCYTE Test and to re-launch the test upon receiving regulatory clearance.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Development Stage Risk</font></u></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">From April 30, 2009 (inception) through September 30, 2013, the Company earned $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,068,687</font> in revenue from the sale of its products and laboratory services. The Company&#8217;s activities have been accounted for as those of a &#8220;Development Stage Enterprise&#8221; as set forth in Accounting Standards Codification (&#8220;ASC&#8221;) 915 &#8220;Development Stage Entities&#8221;, which was previously Statement of Financial Accounting Standards No. 7 (&#8220;SFAS 7&#8221;). Among the disclosures required by ASC 915 are that the Company&#8217;s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders&#8217; equity and cash flows disclose activity since the date of the Company&#8217;s inception.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company&#8217;s business plan will be successfully executed. The Company&#8217;s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
400000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <strong><font style="FONT-SIZE: 10pt">Use of Estimates:</font></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
228841 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2012 atos Loss On Reduction Of Inventory
LossOnReductionOfInventory
29884 USD
us-gaap Profit Loss
ProfitLoss
-8026984 USD
us-gaap Profit Loss
ProfitLoss
-3374249 USD
us-gaap Profit Loss
ProfitLoss
-17758892 USD
atos Common Shares Issued For Services
CommonSharesIssuedForServices
144391 USD
atos Common Shares Issued For Services
CommonSharesIssuedForServices
0 USD
atos Common Shares Issued For Services
CommonSharesIssuedForServices
215392 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1187717 USD
us-gaap Share Based Compensation
ShareBasedCompensation
96251 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1479981 USD
atos Loss On Reduction Of Inventory
LossOnReductionOfInventory
0 USD
atos Loss On Reduction Of Inventory
LossOnReductionOfInventory
29884 USD
atos Loss On Reduction Of Inventory
LossOnReductionOfInventory
121910 USD
atos Loan Initiation Fee Accrued For Notes Payable
LoanInitiationFeeAccruedForNotesPayable
0 USD
atos Loan Initiation Fee Accrued For Notes Payable
LoanInitiationFeeAccruedForNotesPayable
0 USD
atos Loan Initiation Fee Accrued For Notes Payable
LoanInitiationFeeAccruedForNotesPayable
2000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
350536 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25586 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
496711 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-79608 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-37086 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7335 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
528179 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
29884 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
121910 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-71439 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8791 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
51194 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-43160 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-30589 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31131 USD
atos Increase Decrease In Accrued Payroll
IncreaseDecreaseInAccruedPayroll
149493 USD
atos Increase Decrease In Accrued Payroll
IncreaseDecreaseInAccruedPayroll
0 USD
atos Increase Decrease In Accrued Payroll
IncreaseDecreaseInAccruedPayroll
149493 USD
atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
60753 USD
atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0 USD
atos Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
60753 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
386514 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
174183 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-304626 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1491014 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1322756 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
20300 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
20300 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6182060 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1967626 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14007675 USD
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
346007 USD
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
0 USD
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
537054 USD
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
54667 USD
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
0 USD
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
135133 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-400674 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-672187 USD
atos Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
12551098 USD
atos Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
400000 USD
atos Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
22375423 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-750000 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
75375 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-2000 USD
atos Proceeds From Repayments Of Commercial Line Of Credit
ProceedsFromRepaymentsOfCommercialLineOfCredit
0 USD
atos Proceeds From Repayments Of Commercial Line Of Credit
ProceedsFromRepaymentsOfCommercialLineOfCredit
750000 USD
atos Proceeds From Repayments Of Commercial Line Of Credit
ProceedsFromRepaymentsOfCommercialLineOfCredit
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12551098 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
475375 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22373423 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5968364 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1492251 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7693561 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1910821 USD
atos Common Stock And Warrants Issued For Assets Purchase
CommonStockAndWarrantsIssuedForAssetsPurchase
4674853 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
418570 USD
us-gaap Interest Paid
InterestPaid
359 USD
us-gaap Interest Paid
InterestPaid
13892 USD
us-gaap Interest Paid
InterestPaid
33067 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
250 USD
atos Common Stock And Warrants Issued For Assets Purchase
CommonStockAndWarrantsIssuedForAssetsPurchase
0 USD
atos Common Stock And Warrants Issued For Assets Purchase
CommonStockAndWarrantsIssuedForAssetsPurchase
4674853 USD
atos Options Issued For Previously Accrued Director Compensation
OptionsIssuedForPreviouslyAccruedDirectorCompensation
0 USD
atos Options Issued For Previously Accrued Director Compensation
OptionsIssuedForPreviouslyAccruedDirectorCompensation
45000 USD
atos Options Issued For Previously Accrued Director Compensation
OptionsIssuedForPreviouslyAccruedDirectorCompensation
45000 USD
atos Commitment Shares Issued For Shares Distributed For Capital Contribution
CommitmentSharesIssuedForSharesDistributedForCapitalContribution
2387250 USD
atos Commitment Shares Issued For Shares Distributed For Capital Contribution
CommitmentSharesIssuedForSharesDistributedForCapitalContribution
0 USD
atos Commitment Shares Issued For Shares Distributed For Capital Contribution
CommitmentSharesIssuedForSharesDistributedForCapitalContribution
2387250 USD
atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
1879058 USD
atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
0 USD
atos Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution
AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution
1879058 USD
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
402840 USD
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0 USD
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
402840 USD
atos Bad Debt Expense
BadDebtExpense
228841 USD
atos Bad Debt Expense
BadDebtExpense
0 USD
atos Bad Debt Expense
BadDebtExpense
228841 USD
CY2013Q3 atos Prepaid Stock Purchase Agreement Service Fee
PrepaidStockPurchaseAgreementServiceFee
508442 USD
CY2012Q4 atos Prepaid Stock Purchase Agreement Service Fee
PrepaidStockPurchaseAgreementServiceFee
0 USD
CY2013Q3 us-gaap Prepaid Insurance
PrepaidInsurance
27445 USD
CY2012Q4 us-gaap Prepaid Insurance
PrepaidInsurance
62551 USD
CY2013Q3 atos Prepaid Maintenance And Support Service Fee
PrepaidMaintenanceAndSupportServiceFee
23499 USD
CY2012Q4 atos Prepaid Maintenance And Support Service Fee
PrepaidMaintenanceAndSupportServiceFee
20000 USD
CY2013Q3 us-gaap Prepaid Taxes
PrepaidTaxes
0 USD
CY2012Q4 us-gaap Prepaid Taxes
PrepaidTaxes
40082 USD
CY2013Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
269771 USD
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
97383 USD
CY2013Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
93665 USD
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
93665 USD
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93930 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31081 USD
CY2013Q3 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
4704853 USD
CY2012Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
4704853 USD
CY2013Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
105133 USD
CY2012Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
50466 USD
CY2013Q3 atos Capitalized New Product Development Costs
CapitalizedNewProductDevelopmentCosts
173766 USD
CY2012Q4 atos Capitalized New Product Development Costs
CapitalizedNewProductDevelopmentCosts
0 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
393073 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
381331 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
378781 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
363902 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
363028 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2526943 USD
CY2013Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2013Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7443561 USD
CY2012Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1475197 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
380767 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
62451 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
0 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2013Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
443218 USD
us-gaap Depreciation
Depreciation
62849 USD
us-gaap Depreciation
Depreciation
12970 USD
CY2013Q3 atos Total Shares Authorized
TotalSharesAuthorized
85000000 shares
CY2010Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.26332
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4775550 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1052137 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1425394 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
221522 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5546 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2246651 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1044549 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2090475 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.79
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.99
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.21
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.79
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.53
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.54
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M16D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M29D
us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
862500 shares
CY2012Q3 us-gaap Share Price
SharePrice
5.00
atos Warrants Issued During Period Acquisitions
WarrantsIssuedDuringPeriodAcquisitions
325000 shares
atos Warrants Exercise Price
WarrantsExercisePrice
5.00
atos Warrant Price
WarrantPrice
2.3457
atos Warrant Terms
WarrantTerms
P5Y
CY2010Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.26332
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3604669 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1150416 USD
CY2013Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
297290 USD
CY2012Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
189131 USD
CY2013Q3 atos Accrued Payroll Liabilities
AccruedPayrollLiabilities
40318 USD
CY2012Q4 atos Accrued Payroll Liabilities
AccruedPayrollLiabilities
0 USD
CY2013Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
19881 USD
CY2012Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
18865 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3812 shares

Files In Submission

Name View Source Status
0001144204-13-060511-index-headers.html Edgar Link pending
0001144204-13-060511-index.html Edgar Link pending
0001144204-13-060511.txt Edgar Link pending
0001144204-13-060511-xbrl.zip Edgar Link pending
atos-20130930.xml Edgar Link completed
atos-20130930.xsd Edgar Link pending
atos-20130930_cal.xml Edgar Link unprocessable
atos-20130930_def.xml Edgar Link unprocessable
atos-20130930_lab.xml Edgar Link unprocessable
atos-20130930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlogo.jpg Edgar Link pending
v359837_10q.htm Edgar Link pending
v359837_ex10-1.htm Edgar Link pending
v359837_ex10-2.htm Edgar Link pending
v359837_ex31-1.htm Edgar Link pending
v359837_ex31-2.htm Edgar Link pending
v359837_ex32-1.htm Edgar Link pending
v359837_ex32-2.htm Edgar Link pending
v359837_ex4-1.htm Edgar Link pending